I don't want to rain (albeit slightly) on your parade but re-read this:
"Since it (Phase IIb trial) is not designed or powered to provide a definitive answer on the effectiveness of Cvac, it is very unlikely to fail from an efficacy perspective"
Phase III will be designed and powered to provide the answer about efficacy. Phase IIb is about safety. Therefore you cannot draw conclusions about efficacy from the Phase IIb trial. That is what he said but you have over interpreted his comment about efficacy. You CANNOT read between the lines and draw conclusions about efficacy.
Your enthusiasm is obvious. But it is also obvious that despite all the positivity around cVac, PRR still has a some important hurdles to jump.
But it sure is looking good from my perspective that's for sure. For a speccy that is ;)
PRR Price at posting:
23.7¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)